Copy Number–Driven COX19 Promotes Colorectal Cancer Growth and Represents a Potential Therapeutic Target of Olmesartan

Background/Aim Colorectal cancer (CRC) is a leading cause of cancer‐related mortality worldwide. This study aimed to identify tumor‐associated genes in CRC and explore potential therapeutic agents by analyzing chromosomal amplification. Methods DNA copy number variation (CNV) and mRNA expression data from The Cancer Genome Atlas (TCGA) and Cancer Cell Line Encyclopedia (CCLE) were analyzed. We focused on cytochrome c oxidase assembly factor 19 (COX19) as a candidate tumor‐associated gene and examined its clinicopathological and prognostic relevance. Single‐cell RNA sequencing and immunohistochemical analyses were performed. Pathway and drug sensitivity analyses were conducted, followed by in vitro validation of candidate compounds. Results COX19, a mitochondrial complex IV assembly factor, was significantly amplified and overexpressed in CRC. High COX19 expression correlated with poor prognosis and was predominantly observed in tumor epithelial cells. Gene set enrichment analysis (GSEA) suggested suppression of apoptosis in COX19 ‐high tumors. Drug sensitivity analysis identified olmesartan as a candidate therapeutic agent. Olmesartan suppressed the proliferative capacity of COX19 ‐overexpressing CRC cells, whereas COX19 knockout reduced sensitivity to olmesartan. Olmesartan also increased miR‐205‐3p expression, and miR‐205‐3p inhibition partially attenuated its antiproliferative effect. Conclusion COX19 may be a tumor‐associated gene linked to tumor progression and poor prognosis in CRC. Olmesartan may represent a potential therapeutic candidate for COX19 ‐high CRC. Its antiproliferative effects may involve miR‐205‐3p, although the underlying mechanism requires further validation.

Authors

Institutions

Publication Details

Journal
Annals of Gastroenterological Surgery
Published
2026-11-18
DOI
https://doi.org/10.1002/ags3.70303
Primary Topic
Colorectal Cancer Treatments and Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Copy Number–Driven COX19 Promotes Colorectal Cancer Growth and Represents a Potential Therapeutic Target of Olmesartan

Takaaki Masuda, Koji Ando, Yoshiki Hiraki, Tomoharu Yoshizumi et al.
1 links
Annals of Gastroenterological Surgery
Colorectal Cancer Treatments and Studies
article

Copy Number–Driven COX19 Promotes Colorectal Cancer Growth and Represents a Potential Therapeutic Target of Olmesartan

Takaaki Masuda, Koji Ando, Yoshiki Hiraki, Tomoharu Yoshizumi, Hajime Otsu, Qingjiang Hu, Taro Tobo, Koshi Mimori, Yusuke Yonemura, Koto Kawata
article en

Abstract

Background/Aim Colorectal cancer (CRC) is a leading cause of cancer‐related mortality worldwide. This study aimed to identify tumor‐associated genes in CRC and explore potential therapeutic agents by analyzing chromosomal amplification. Methods DNA copy number variation (CNV) and mRNA expression data from The Cancer Genome Atlas (TCGA) and Cancer Cell Line Encyclopedia (CCLE) were analyzed. We focused on cytochrome c oxidase assembly factor 19 (COX19) as a candidate tumor‐associated gene and examined its clinicopathological and prognostic relevance. Single‐cell RNA sequencing and immunohistochemical analyses were performed. Pathway and drug sensitivity analyses were conducted, followed by in vitro validation of candidate compounds. Results COX19, a mitochondrial complex IV assembly factor, was significantly amplified and overexpressed in CRC. High COX19 expression correlated with poor prognosis and was predominantly observed in tumor epithelial cells. Gene set enrichment analysis (GSEA) suggested suppression of apoptosis in COX19 ‐high tumors. Drug sensitivity analysis identified olmesartan as a candidate therapeutic agent. Olmesartan suppressed the proliferative capacity of COX19 ‐overexpressing CRC cells, whereas COX19 knockout reduced sensitivity to olmesartan. Olmesartan also increased miR‐205‐3p expression, and miR‐205‐3p inhibition partially attenuated its antiproliferative effect. Conclusion COX19 may be a tumor‐associated gene linked to tumor progression and poor prognosis in CRC. Olmesartan may represent a potential therapeutic candidate for COX19 ‐high CRC. Its antiproliferative effects may involve miR‐205‐3p, although the underlying mechanism requires further validation.

Annals of Gastroenterological SurgeryVol. 11(1)
Kyushu University (JP), Kyushu University Beppu Hospital (JP), Kōchi University (JP)
Takeda Science Foundation, Japan Agency for Medical Research and Development, Princess Takamatsu Cancer Research Fund, Japan Society for the Promotion of Science
Good health and well-being
Colorectal Cancer Treatments and Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon